 | • レポートコード：QFJ1-4619 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、123ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、経口抗糖尿病薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（液体、カプセル、錠剤）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・経口抗糖尿病薬の市場動向 ・企業の競争状況、市場シェア ・経口抗糖尿病薬の種類別市場規模と予測2016-2027（液体、カプセル、錠剤） ・経口抗糖尿病薬の用途別市場規模と予測2016-2027（病院薬局、小売薬局、オンライン薬局） ・経口抗糖尿病薬の北米市場規模2016-2027（アメリカ、カナダ） ・経口抗糖尿病薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・経口抗糖尿病薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・経口抗糖尿病薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・経口抗糖尿病薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Sanofi、Eli Lilly、AstraZeneca plc、Astellas Pharma Inc、Johnson & Johnson (Janssen Pharmaceuticals)、Boehringer Ingelheim、Merck、Takeda、Bristol Myers Squibb、Novartis、Pfizer、Abbott、Biocon、Sunpharma、Novo Nordisk、Piramal Healthcare、Bayer Healthcare、Dr. Reddy’s Laboratories Ltd、Glenmark Pharmaceuticals Ltd） ・結論 |
Diabetes is a chronic disease that occurs when the body cannot effectively use the produced insulin or the pancreas does not produce sufficient insulin. The pancreas is an organ that sits behind the stomach and releases hormones into the digestive system. Diabetes is categorized by increased levels of blood glucose, which can cause severe damage to blood vessels, heart, kidneys, nerves, and eyes. Diabetes is also called hyperglycemia or raised blood sugar. Insulin is a hormone that regulates the blood sugar level in body. Continuous increase in blood sugar leads to diabetes. Uncontrollable diabetes can damage the nervous system and other body systems. Diabetes is of two types: type 1 and type 2. Type 1 diabetes, also known as juvenile diabetes or insulin-dependent diabetes, arises when the immune system misguidedly attacks and kills the beta cells of the pancreas. In type 1 diabetes, little or no insulin is released into the body, owing to this sugar builds up in the blood instead of being used as energy. Type 1 diabetes is rare, and only 10% of people with diabetes have type 1 diabetes. It commonly occurs in childhood or adolescence. Type 2 diabetes arises when the body cannot appropriately use the insulin that is released or does not make enough insulin. As a consequence, sugar builds up in the blood instead of being used as energy. About 90% of people with diabetes have type 2 diabetes.
Market Analysis and Insights: Global Oral Anti-diabetes Drugs Market
The global Oral Anti-diabetes Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Oral Anti-diabetes Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Oral Anti-diabetes Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Oral Anti-diabetes Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Oral Anti-diabetes Drugs market.
Global Oral Anti-diabetes Drugs Scope and Market Size
Oral Anti-diabetes Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Oral Anti-diabetes Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Distribution Channel in terms of revenue and forecast for the period 2016-2027.
Segment by Type
by Type
Liquid
Capsule
Tablet
by Drug Class
Sulfonylureas
Meglitinides
Biguanides
Others
Segment by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Sanofi
Eli Lilly
AstraZeneca plc
Astellas Pharma Inc
Johnson & Johnson (Janssen Pharmaceuticals)
Boehringer Ingelheim
Merck
Takeda
Bristol Myers Squibb
Novartis
Pfizer
Abbott
Biocon
Sunpharma
Novo Nordisk
Piramal Healthcare
Bayer Healthcare
Dr. Reddy’s Laboratories Ltd
Glenmark Pharmaceuticals Ltd
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oral Anti-diabetes Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Liquid
1.2.3 Capsule
1.2.4 Tablet
1.3 Market by Application
1.3.1 Global Oral Anti-diabetes Drugs Market Share by Distribution Channel: 2016 VS 2021 VS 2027
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Oral Anti-diabetes Drugs Market Perspective (2016-2027)
2.2 Oral Anti-diabetes Drugs Growth Trends by Regions
2.2.1 Oral Anti-diabetes Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Oral Anti-diabetes Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Oral Anti-diabetes Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Oral Anti-diabetes Drugs Industry Dynamic
2.3.1 Oral Anti-diabetes Drugs Market Trends
2.3.2 Oral Anti-diabetes Drugs Market Drivers
2.3.3 Oral Anti-diabetes Drugs Market Challenges
2.3.4 Oral Anti-diabetes Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oral Anti-diabetes Drugs Players by Revenue
3.1.1 Global Top Oral Anti-diabetes Drugs Players by Revenue (2016-2021)
3.1.2 Global Oral Anti-diabetes Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Oral Anti-diabetes Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Oral Anti-diabetes Drugs Revenue
3.4 Global Oral Anti-diabetes Drugs Market Concentration Ratio
3.4.1 Global Oral Anti-diabetes Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oral Anti-diabetes Drugs Revenue in 2020
3.5 Oral Anti-diabetes Drugs Key Players Head office and Area Served
3.6 Key Players Oral Anti-diabetes Drugs Product Solution and Service
3.7 Date of Enter into Oral Anti-diabetes Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oral Anti-diabetes Drugs Breakdown Data by Type
4.1 Global Oral Anti-diabetes Drugs Historic Market Size by Type (2016-2021)
4.2 Global Oral Anti-diabetes Drugs Forecasted Market Size by Type (2022-2027)
5 Oral Anti-diabetes Drugs Breakdown Data by Distribution Channel
5.1 Global Oral Anti-diabetes Drugs Historic Market Size by Distribution Channel (2016-2021)
5.2 Global Oral Anti-diabetes Drugs Forecasted Market Size by Distribution Channel (2022-2027)
6 North America
6.1 North America Oral Anti-diabetes Drugs Market Size (2016-2027)
6.2 North America Oral Anti-diabetes Drugs Market Size by Type
6.2.1 North America Oral Anti-diabetes Drugs Market Size by Type (2016-2021)
6.2.2 North America Oral Anti-diabetes Drugs Market Size by Type (2022-2027)
6.2.3 North America Oral Anti-diabetes Drugs Market Size by Type (2016-2027)
6.3 North America Oral Anti-diabetes Drugs Market Size by Distribution Channel
6.3.1 North America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021)
6.3.2 North America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027)
6.3.3 North America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2027)
6.4 North America Oral Anti-diabetes Drugs Market Size by Country
6.4.1 North America Oral Anti-diabetes Drugs Market Size by Country (2016-2021)
6.4.2 North America Oral Anti-diabetes Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Oral Anti-diabetes Drugs Market Size (2016-2027)
7.2 Europe Oral Anti-diabetes Drugs Market Size by Type
7.2.1 Europe Oral Anti-diabetes Drugs Market Size by Type (2016-2021)
7.2.2 Europe Oral Anti-diabetes Drugs Market Size by Type (2022-2027)
7.2.3 Europe Oral Anti-diabetes Drugs Market Size by Type (2016-2027)
7.3 Europe Oral Anti-diabetes Drugs Market Size by Distribution Channel
7.3.1 Europe Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021)
7.3.2 Europe Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027)
7.3.3 Europe Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2027)
7.4 Europe Oral Anti-diabetes Drugs Market Size by Country
7.4.1 Europe Oral Anti-diabetes Drugs Market Size by Country (2016-2021)
7.4.2 Europe Oral Anti-diabetes Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Oral Anti-diabetes Drugs Market Size (2016-2027)
8.2 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Type
8.2.1 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Distribution Channel
8.3.1 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021)
8.3.2 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027)
8.3.3 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2027)
8.4 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region
8.4.1 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Oral Anti-diabetes Drugs Market Size (2016-2027)
9.2 Latin America Oral Anti-diabetes Drugs Market Size by Type
9.2.1 Latin America Oral Anti-diabetes Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Oral Anti-diabetes Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Oral Anti-diabetes Drugs Market Size by Type (2016-2027)
9.3 Latin America Oral Anti-diabetes Drugs Market Size by Distribution Channel
9.3.1 Latin America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021)
9.3.2 Latin America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027)
9.3.3 Latin America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2027)
9.4 Latin America Oral Anti-diabetes Drugs Market Size by Country
9.4.1 Latin America Oral Anti-diabetes Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Oral Anti-diabetes Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oral Anti-diabetes Drugs Market Size (2016-2027)
10.2 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Type
10.2.1 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Distribution Channel
10.3.1 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021)
10.3.2 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027)
10.3.3 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2027)
10.4 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country
10.4.1 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Oral Anti-diabetes Drugs Introduction
11.1.4 Sanofi Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.1.5 Sanofi Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Details
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Oral Anti-diabetes Drugs Introduction
11.2.4 Eli Lilly Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.2.5 Eli Lilly Recent Development
11.3 AstraZeneca plc
11.3.1 AstraZeneca plc Company Details
11.3.2 AstraZeneca plc Business Overview
11.3.3 AstraZeneca plc Oral Anti-diabetes Drugs Introduction
11.3.4 AstraZeneca plc Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.3.5 AstraZeneca plc Recent Development
11.4 Astellas Pharma Inc
11.4.1 Astellas Pharma Inc Company Details
11.4.2 Astellas Pharma Inc Business Overview
11.4.3 Astellas Pharma Inc Oral Anti-diabetes Drugs Introduction
11.4.4 Astellas Pharma Inc Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.4.5 Astellas Pharma Inc Recent Development
11.5 Johnson & Johnson (Janssen Pharmaceuticals)
11.5.1 Johnson & Johnson (Janssen Pharmaceuticals) Company Details
11.5.2 Johnson & Johnson (Janssen Pharmaceuticals) Business Overview
11.5.3 Johnson & Johnson (Janssen Pharmaceuticals) Oral Anti-diabetes Drugs Introduction
11.5.4 Johnson & Johnson (Janssen Pharmaceuticals) Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.5.5 Johnson & Johnson (Janssen Pharmaceuticals) Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Details
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Oral Anti-diabetes Drugs Introduction
11.6.4 Boehringer Ingelheim Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.6.5 Boehringer Ingelheim Recent Development
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Oral Anti-diabetes Drugs Introduction
11.7.4 Merck Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.7.5 Merck Recent Development
11.8 Takeda
11.8.1 Takeda Company Details
11.8.2 Takeda Business Overview
11.8.3 Takeda Oral Anti-diabetes Drugs Introduction
11.8.4 Takeda Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.8.5 Takeda Recent Development
11.9 Bristol Myers Squibb
11.9.1 Bristol Myers Squibb Company Details
11.9.2 Bristol Myers Squibb Business Overview
11.9.3 Bristol Myers Squibb Oral Anti-diabetes Drugs Introduction
11.9.4 Bristol Myers Squibb Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.9.5 Bristol Myers Squibb Recent Development
11.10 Novartis
11.10.1 Novartis Company Details
11.10.2 Novartis Business Overview
11.10.3 Novartis Oral Anti-diabetes Drugs Introduction
11.10.4 Novartis Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.10.5 Novartis Recent Development
11.11 Pfizer
11.11.1 Pfizer Company Details
11.11.2 Pfizer Business Overview
11.11.3 Pfizer Oral Anti-diabetes Drugs Introduction
11.11.4 Pfizer Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.11.5 Pfizer Recent Development
11.12 Abbott
11.12.1 Abbott Company Details
11.12.2 Abbott Business Overview
11.12.3 Abbott Oral Anti-diabetes Drugs Introduction
11.12.4 Abbott Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.12.5 Abbott Recent Development
11.13 Biocon
11.13.1 Biocon Company Details
11.13.2 Biocon Business Overview
11.13.3 Biocon Oral Anti-diabetes Drugs Introduction
11.13.4 Biocon Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.13.5 Biocon Recent Development
11.14 Sunpharma
11.14.1 Sunpharma Company Details
11.14.2 Sunpharma Business Overview
11.14.3 Sunpharma Oral Anti-diabetes Drugs Introduction
11.14.4 Sunpharma Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.14.5 Sunpharma Recent Development
11.15 Novo Nordisk
11.15.1 Novo Nordisk Company Details
11.15.2 Novo Nordisk Business Overview
11.15.3 Novo Nordisk Oral Anti-diabetes Drugs Introduction
11.15.4 Novo Nordisk Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.15.5 Novo Nordisk Recent Development
11.16 Piramal Healthcare
11.16.1 Piramal Healthcare Company Details
11.16.2 Piramal Healthcare Business Overview
11.16.3 Piramal Healthcare Oral Anti-diabetes Drugs Introduction
11.16.4 Piramal Healthcare Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.16.5 Piramal Healthcare Recent Development
11.17 Bayer Healthcare
11.17.1 Bayer Healthcare Company Details
11.17.2 Bayer Healthcare Business Overview
11.17.3 Bayer Healthcare Oral Anti-diabetes Drugs Introduction
11.17.4 Bayer Healthcare Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.17.5 Bayer Healthcare Recent Development
11.18 Dr. Reddy’s Laboratories Ltd
11.18.1 Dr. Reddy’s Laboratories Ltd Company Details
11.18.2 Dr. Reddy’s Laboratories Ltd Business Overview
11.18.3 Dr. Reddy’s Laboratories Ltd Oral Anti-diabetes Drugs Introduction
11.18.4 Dr. Reddy’s Laboratories Ltd Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
11.18.5 Dr. Reddy’s Laboratories Ltd Recent Development
11.18 Glenmark Pharmaceuticals Ltd
.1 Glenmark Pharmaceuticals Ltd Company Details
.2 Glenmark Pharmaceuticals Ltd Business Overview
.3 Glenmark Pharmaceuticals Ltd Oral Anti-diabetes Drugs Introduction
.4 Glenmark Pharmaceuticals Ltd Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
.5 Glenmark Pharmaceuticals Ltd Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Oral Anti-diabetes Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Liquid
Table 3. Key Players of Capsule
Table 4. Key Players of Tablet
Table 5. Global Oral Anti-diabetes Drugs Market Size Growth by Distribution Channel (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Oral Anti-diabetes Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Oral Anti-diabetes Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Oral Anti-diabetes Drugs Market Share by Regions (2016-2021)
Table 9. Global Oral Anti-diabetes Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Oral Anti-diabetes Drugs Market Share by Regions (2022-2027)
Table 11. Oral Anti-diabetes Drugs Market Trends
Table 12. Oral Anti-diabetes Drugs Market Drivers
Table 13. Oral Anti-diabetes Drugs Market Challenges
Table 14. Oral Anti-diabetes Drugs Market Restraints
Table 15. Global Oral Anti-diabetes Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Oral Anti-diabetes Drugs Market Share by Players (2016-2021)
Table 17. Global Top Oral Anti-diabetes Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oral Anti-diabetes Drugs as of 2020)
Table 18. Ranking of Global Top Oral Anti-diabetes Drugs Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Oral Anti-diabetes Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Oral Anti-diabetes Drugs Product Solution and Service
Table 22. Date of Enter into Oral Anti-diabetes Drugs Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Oral Anti-diabetes Drugs Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Oral Anti-diabetes Drugs Revenue Market Share by Type (2016-2021)
Table 26. Global Oral Anti-diabetes Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Oral Anti-diabetes Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Oral Anti-diabetes Drugs Market Size Share by Distribution Channel (2016-2021) & (US$ Million)
Table 29. Global Oral Anti-diabetes Drugs Revenue Market Share by Distribution Channel (2016-2021)
Table 30. Global Oral Anti-diabetes Drugs Forecasted Market Size by Distribution Channel (2022-2027) (US$ Million)
Table 31. Global Oral Anti-diabetes Drugs Revenue Market Share by Distribution Channel (2022-2027) & (US$ Million)
Table 32. North America Oral Anti-diabetes Drugs Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Oral Anti-diabetes Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021) (US$ Million)
Table 35. North America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027) & (US$ Million)
Table 36. North America Oral Anti-diabetes Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Oral Anti-diabetes Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Oral Anti-diabetes Drugs Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Oral Anti-diabetes Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021) (US$ Million)
Table 41. Europe Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027) & (US$ Million)
Table 42. Europe Oral Anti-diabetes Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Oral Anti-diabetes Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Oral Anti-diabetes Drugs Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Oral Anti-diabetes Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021) (US$ Million)
Table 47. Asia-Pacific Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Oral Anti-diabetes Drugs Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Oral Anti-diabetes Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021) (US$ Million)
Table 53. Latin America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027) & (US$ Million)
Table 54. Latin America Oral Anti-diabetes Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Oral Anti-diabetes Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Oral Anti-diabetes Drugs Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Oral Anti-diabetes Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021) (US$ Million)
Table 59. Middle East & Africa Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 62. Sanofi Company Details
Table 63. Sanofi Business Overview
Table 64. Sanofi Oral Anti-diabetes Drugs Product
Table 65. Sanofi Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 66. Sanofi Recent Development
Table 67. Eli Lilly Company Details
Table 68. Eli Lilly Business Overview
Table 69. Eli Lilly Oral Anti-diabetes Drugs Product
Table 70. Eli Lilly Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 71. Eli Lilly Recent Development
Table 72. AstraZeneca plc Company Details
Table 73. AstraZeneca plc Business Overview
Table 74. AstraZeneca plc Oral Anti-diabetes Drugs Product
Table 75. AstraZeneca plc Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 76. AstraZeneca plc Recent Development
Table 77. Astellas Pharma Inc Company Details
Table 78. Astellas Pharma Inc Business Overview
Table 79. Astellas Pharma Inc Oral Anti-diabetes Drugs Product
Table 80. Astellas Pharma Inc Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 81. Astellas Pharma Inc Recent Development
Table 82. Johnson & Johnson (Janssen Pharmaceuticals) Company Details
Table 83. Johnson & Johnson (Janssen Pharmaceuticals) Business Overview
Table 84. Johnson & Johnson (Janssen Pharmaceuticals) Oral Anti-diabetes Drugs Product
Table 85. Johnson & Johnson (Janssen Pharmaceuticals) Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 86. Johnson & Johnson (Janssen Pharmaceuticals) Recent Development
Table 87. Boehringer Ingelheim Company Details
Table 88. Boehringer Ingelheim Business Overview
Table 89. Boehringer Ingelheim Oral Anti-diabetes Drugs Product
Table 90. Boehringer Ingelheim Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 91. Boehringer Ingelheim Recent Development
Table 92. Merck Company Details
Table 93. Merck Business Overview
Table 94. Merck Oral Anti-diabetes Drugs Product
Table 95. Merck Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 96. Merck Recent Development
Table 97. Takeda Company Details
Table 98. Takeda Business Overview
Table 99. Takeda Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 100. Takeda Recent Development
Table 101. Bristol Myers Squibb Company Details
Table 102. Bristol Myers Squibb Business Overview
Table 103. Bristol Myers Squibb Oral Anti-diabetes Drugs Product
Table 104. Bristol Myers Squibb Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 105. Bristol Myers Squibb Recent Development
Table 106. Novartis Company Details
Table 107. Novartis Business Overview
Table 108. Novartis Oral Anti-diabetes Drugs Product
Table 109. Novartis Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 110. Novartis Recent Development
Table 111. Pfizer Company Details
Table 112. Pfizer Business Overview
Table 113. Pfizer Oral Anti-diabetes Drugs Product
Table 114. Pfizer Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 115. Pfizer Recent Development
Table 116. Abbott Company Details
Table 117. Abbott Business Overview
Table 118. Abbott Oral Anti-diabetes Drugs Product
Table 119. Abbott Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 120. Abbott Recent Development
Table 121. Biocon Company Details
Table 122. Biocon Business Overview
Table 123. Biocon Oral Anti-diabetes Drugs Product
Table 124. Biocon Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 125. Biocon Recent Development
Table 126. Sunpharma Company Details
Table 127. Sunpharma Business Overview
Table 128. Sunpharma Oral Anti-diabetes Drugs Product
Table 129. Sunpharma Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 130. Sunpharma Recent Development
Table 131. Novo Nordisk Company Details
Table 132. Novo Nordisk Business Overview
Table 133. Novo Nordisk Oral Anti-diabetes Drugs Product
Table 134. Novo Nordisk Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 135. Novo Nordisk Recent Development
Table 136. Piramal Healthcare Company Details
Table 137. Piramal Healthcare Business Overview
Table 138. Piramal Healthcare Oral Anti-diabetes Drugs Product
Table 139. Piramal Healthcare Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 140. Piramal Healthcare Recent Development
Table 141. Bayer Healthcare Company Details
Table 142. Bayer Healthcare Business Overview
Table 143. Bayer Healthcare Oral Anti-diabetes Drugs Product
Table 144. Bayer Healthcare Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 145. Bayer Healthcare Recent Development
Table 146. Dr. Reddy’s Laboratories Ltd Company Details
Table 147. Dr. Reddy’s Laboratories Ltd Business Overview
Table 148. Dr. Reddy’s Laboratories Ltd Oral Anti-diabetes Drugs Product
Table 149. Dr. Reddy’s Laboratories Ltd Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 150. Dr. Reddy’s Laboratories Ltd Recent Development
Table 151. Glenmark Pharmaceuticals Ltd Company Details
Table 152. Glenmark Pharmaceuticals Ltd Business Overview
Table 153. Glenmark Pharmaceuticals Ltd Oral Anti-diabetes Drugs Product
Table 154. Glenmark Pharmaceuticals Ltd Revenue in Oral Anti-diabetes Drugs Business (2016-2021) & (US$ Million)
Table 155. Glenmark Pharmaceuticals Ltd Recent Development
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oral Anti-diabetes Drugs Market Share by Type: 2020 VS 2027
Figure 2. Liquid Features
Figure 3. Capsule Features
Figure 4. Tablet Features
Figure 5. Global Oral Anti-diabetes Drugs Market Share by Distribution Channel: 2020 VS 2027
Figure 6. Hospital Pharmacies Case Studies
Figure 7. Retail Pharmacies Case Studies
Figure 8. Online Pharmacies Case Studies
Figure 9. Oral Anti-diabetes Drugs Report Years Considered
Figure 10. Global Oral Anti-diabetes Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Oral Anti-diabetes Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Oral Anti-diabetes Drugs Market Share by Regions: 2020 VS 2027
Figure 13. Global Oral Anti-diabetes Drugs Market Share by Regions (2022-2027)
Figure 14. Global Oral Anti-diabetes Drugs Market Share by Players in 2020
Figure 15. Global Top Oral Anti-diabetes Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oral Anti-diabetes Drugs as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Oral Anti-diabetes Drugs Revenue in 2020
Figure 17. Global Oral Anti-diabetes Drugs Revenue Market Share by Type (2016-2021)
Figure 18. Global Oral Anti-diabetes Drugs Revenue Market Share by Type (2022-2027)
Figure 19. North America Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Oral Anti-diabetes Drugs Market Share by Type (2016-2027)
Figure 21. North America Oral Anti-diabetes Drugs Market Share by Distribution Channel (2016-2027)
Figure 22. North America Oral Anti-diabetes Drugs Market Share by Country (2016-2027)
Figure 23. United States Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Oral Anti-diabetes Drugs Market Share by Type (2016-2027)
Figure 27. Europe Oral Anti-diabetes Drugs Market Share by Distribution Channel (2016-2027)
Figure 28. Europe Oral Anti-diabetes Drugs Market Share by Country (2016-2027)
Figure 29. Germany Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Oral Anti-diabetes Drugs Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Oral Anti-diabetes Drugs Market Share by Distribution Channel (2016-2027)
Figure 38. Asia-Pacific Oral Anti-diabetes Drugs Market Share by Region (2016-2027)
Figure 39. China Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Oral Anti-diabetes Drugs Market Share by Type (2016-2027)
Figure 47. Latin America Oral Anti-diabetes Drugs Market Share by Distribution Channel (2016-2027)
Figure 48. Latin America Oral Anti-diabetes Drugs Market Share by Country (2016-2027)
Figure 49. Mexico Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Oral Anti-diabetes Drugs Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Oral Anti-diabetes Drugs Market Share by Distribution Channel (2016-2027)
Figure 54. Middle East & Africa Oral Anti-diabetes Drugs Market Share by Country (2016-2027)
Figure 55. Turkey Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Oral Anti-diabetes Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Sanofi Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 59. Eli Lilly Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 60. AstraZeneca plc Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 61. Astellas Pharma Inc Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 62. Johnson & Johnson (Janssen Pharmaceuticals) Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 63. Boehringer Ingelheim Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 64. Merck Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 65. Takeda Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 66. Bristol Myers Squibb Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 67. Novartis Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 68. Pfizer Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 69. Abbott Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 70. Biocon Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 71. Sunpharma Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 72. Novo Nordisk Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 73. Piramal Healthcare Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 74. Bayer Healthcare Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 75. Dr. Reddy’s Laboratories Ltd Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 76. Glenmark Pharmaceuticals Ltd Revenue Growth Rate in Oral Anti-diabetes Drugs Business (2016-2021)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed
世界のインスリン非依存型糖尿病治療薬市場規模・現状・予測（2021年-2027年） Diabetes is a metabolic disease, wherein the body is either unable to secret insulin (type 1 diabetes) or is unable to utilize the generated insulin (type 2 diabetes). Market Analysis and Insights: Global Non Insulin Anti diabetes Drugs Market The global Non Insulin Anti diabetes Drugs market size i…- 世界の抗喘息薬＆COPD薬市場規模・現状・予測（2021年-2027年） The anti-asthmatics and chronic obstructive pulmonary disease (COPD) market consists of sales of anti-asthmatics and chronic obstructive pulmonary disease (COPD) drugs which are used to relieve the frequency of acute attacks of asthma, emphysema, chronic bronchitis, and nocturnal awakenings. The cla…
- 世界の糖尿病治療薬市場規模・現状・予測（2021年-2027年） Diabetes drugs are treatments for diabetes by lowering the sugar lower in the blood. Diabetes is a kind of disease with common symptoms such as frequent urination, increased thirst and weight loss. The most common drugs used are insulin and oral medications. Market Analysis and Insights: Global Diab…
- 世界の非ステロイド性抗炎症薬（NSAID）市場規模・現状・予測（2021年-2027年） Nonsteroidal anti-inflammatory drugs (NSAIDs) are a drug class that reduce pain, decrease fever, prevent blood clots and, in higher doses, decrease inflammation. Side effects depend on the specific drug, but largely include an increased risk of gastrointestinal ulcers and bleeds, heart attack and ki…
- 世界の抗パーキンソン薬市場規模・現状・予測（2021年-2027年） Anti-Parkinson Drugs are drugs used to treat Parkinson's disease. The most commonly used Anti-Parkinson Drugs act on the dopaminergic system of the striatum and basal ganglia, or are central muscarinic antagonists. Market Analysis and Insights: Global Anti-Parkinson Drugs Market The global Anti-Park…